Executive summary: U.S. Patent No. 11,147,790 protects a tightly defined topical cantharidin formulation, related single-use applicators, and treatment methods for molluscum contagiosum and warts. Its strongest protection is composition-based: a product must contain the listed solvent, film-forming, excipient, sensory, and colorant components within the claim’s approximate concentration ranges. The patent also adds method limitations involving skin residence time, cantharidin penetration, and plasma exposure. The claims are directed to a small-molecule topical product, so biosimilar analysis is not applicable. Generic or competing-product risk is concentrated in formulation design-around, non-infringing delivery systems, and patent-term challenges.
U.S. Patent 11,147,790: Cantharidin Formulation Scope, Claims, and Patent Landscape
What does U.S. Patent 11,147,790 protect?
U.S. Patent No. 11,147,790 protects a cantharidin-based topical composition and products and methods that use it. The supplied claims cover four principal categories:
- A composition containing cantharidin at approximately 0.88% by weight, together with a defined solvent and excipient system.
- Treatment of molluscum contagiosum skin lesions.
- Treatment of warts.
- A single-use applicator containing the claimed composition.
The composition in claim 1 contains:
| Component |
Claimed concentration |
| Cantharidin |
About 0.88 wt% |
| Acetone |
About 60 wt% |
| Ethanol |
About 31.5 wt% |
| Castor oil |
About 1.4 wt% |
| Nitrocellulose |
About 4.5 wt% |
| Hydroxypropyl cellulose |
About 0.88 wt% |
| Camphor |
About 0.92 wt% |
The listed concentrations total approximately 100.08% because the claim uses rounded values and the transition term "about." That wording is important. The claim does not require mathematical identity to exactly 100.000%; it requires a formulation that falls within legally supportable ranges around the stated concentrations.
The patent is formulation-specific rather than a broad claim to cantharidin generally. A competing product that uses cantharidin but materially changes the solvent system, film-forming polymer, concentration profile, or excipient package may avoid literal infringement, subject to the doctrine of equivalents.
How broad is claim 1 of patent 11,147,790?
Claim 1 is an open-ended composition claim because it begins with "a composition comprising." The claim requires each listed component but does not, on its face, exclude additional ingredients.
A potentially infringing formulation would therefore need to contain:
- Cantharidin at approximately 0.88 wt%;
- Acetone at approximately 60 wt%;
- Ethanol at approximately 31.5 wt%;
- Castor oil at approximately 1.4 wt%;
- Nitrocellulose at approximately 4.5 wt%;
- Hydroxypropyl cellulose at approximately 0.88 wt%; and
- Camphor at approximately 0.92 wt%.
The use of "comprising" means that the addition of another excipient does not automatically avoid the claim. A product containing the claimed seven-component system plus a preservative, fragrance, stabilizer, colorant, or bittering agent could still fall within claim 1.
The key infringement issue is concentration. Because every listed concentration is expressed as "about," the scope will depend on intrinsic evidence, the specification, prosecution history, formulation testing, and the ordinary meaning of the term in the field. A formulation with 0.7% cantharidin, for example, cannot be assumed to infringe a claim requiring about 0.88% without a claim-construction and equivalence analysis.
What formulations are protected by claims 6 and 7?
Claims 6 and 7 add optional and closed-formulation protection.
Claim 6 adds:
| Additional component |
Claimed concentration |
| Denatonium benzoate |
About 0.006 wt% |
| Gentian violet |
About 0.0005 wt% |
The claim uses "and/or," so the dependent claim can cover a composition containing denatonium benzoate, gentian violet, or both, depending on the proper construction of the dependency and the underlying specification.
Claim 7 is narrower. It requires a composition that "consists essentially of" the listed components and concentrations. The relevant ingredients are:
- About 0.88 wt% cantharidin;
- About 60 wt% acetone;
- About 31.5 wt% ethanol;
- About 1.4 wt% castor oil;
- About 4.5 wt% nitrocellulose;
- About 0.88 wt% hydroxypropyl cellulose;
- About 0.92 wt% camphor;
- About 0.006 wt% denatonium benzoate; and
- About 0.0005 wt% gentian violet.
"Consists essentially of" generally permits components that do not materially alter the basic and novel characteristics of the composition. It is narrower than "comprising," but not necessarily as restrictive as "consisting of." The commercial consequence is that an added ingredient may avoid claim 7 if it materially changes the formulation’s operation, while a minor additive may not.
What methods of treatment are covered?
Claims 2 and 4 cover administration of the claimed composition to:
- A skin lesion caused by molluscum contagiosum; or
- Warts.
The claims do not require a specific patient age, lesion count, lesion size, body site, or dosing frequency. They require use of the composition of claim 1, which imports all of claim 1’s formulation limitations.
Claim 5 adds a penetration limitation. It covers treatment of warts or molluscum lesions where:
- The composition is administered to the lesion; and
- At least part of the composition remains on the lesion; and
- At least about 10% of administered cantharidin penetrates the wart or lesion.
Dependent claim 13 raises the penetration threshold to at least about 50%. Claim 14 raises it to at least about 90%.
These claims create evidentiary issues. A patent owner would need to establish that the accused product and use satisfy the penetration limitation. Routine clinical use may not directly establish the percentage penetrating into the lesion. The patent’s specification, assay methods, pharmacokinetic data, or expert testimony would likely determine how the limitation is measured.
What residence-time limitations are claimed?
Claims 8 through 11 cover leaving the composition on a molluscum lesion for defined periods:
| Claim |
Residence-time limitation |
| 8 |
Greater than about 12 hours and no more than about 24 hours |
| 9 |
Greater than about 18 hours and no more than about 24 hours |
| 10 |
No more than about 24 hours |
| 11 |
Approximately 24 hours |
Claim 10 is broader than claims 8 and 9 because it does not impose a minimum residence time. Claim 11 is more specific but may be difficult to distinguish from claim 10 depending on the construction of "approximately 24 hours."
Claim 12 further requires that plasma cantharidin concentration be no more than about 3.3 ng/mL after at least 12 hours following administration. This is a pharmacokinetic limitation, not merely a dosing instruction. It may be difficult to prove in an infringement case without clinical or bioanalytical evidence.
What is the patent’s protection for single-use applicators?
Claim 3 covers a single-use applicator device containing the claim 1 composition. The claim does not expressly require a particular applicator geometry, brush, tip, reservoir, handle, dose volume, or packaging configuration.
The device claim can reach a prefilled applicator even if the product is not sold as a conventional bottle. A competing device may avoid literal infringement if it does not contain the claimed formulation, uses a materially different composition, or is not properly characterized as a single-use applicator.
The claim does not necessarily cover every package associated with a cantharidin product. A carton, vial, multi-dose bottle, or applicator sold separately would require a fact-specific analysis.
When does patent 11,147,790 lose exclusivity?
The patent issued on October 19, 2021. The patent’s nominal expiration depends on the earliest effective nonprovisional filing date, any terminal disclaimer, and patent-term adjustment. The relevant public patent record should be used for the final expiration calculation because an issued patent’s term may differ from a simple 20-year calculation. [1]
The patent is not the same as FDA regulatory exclusivity. Patent expiration and FDA exclusivity operate independently:
| Protection type |
Relevance |
| Patent term |
Controls enforceable patent rights, subject to term adjustment and disclaimers |
| New chemical entity exclusivity |
May apply only if FDA classified the active ingredient as a new chemical entity |
| New drug exclusivity |
May protect approved labeling or clinical data for a defined period |
| Orphan-drug exclusivity |
Depends on orphan designation and approval |
| Pediatric exclusivity |
Can add six months to qualifying FDA exclusivity and listed patent terms |
Ycanth, the FDA-approved cantharidin topical product for molluscum contagiosum, was approved on July 21, 2023. FDA approved it for adults and pediatric patients aged 2 years and older. [2] The approval does not establish that every approved-product attribute is covered by patent 11,147,790.
What is the Orange Book status of patent 11,147,790?
The Orange Book listing must be assessed against the specific approved drug product and the patent claims. A patent may be listed if it claims the drug substance, drug product, or an approved method of use under FDA listing rules. The listing of a patent does not itself establish infringement or validity. [3]
For an approved cantharidin product, relevant listing categories may include:
- Formulation claims;
- Applicator or delivery-device claims;
- Method-of-use claims for molluscum contagiosum; and
- Other patents covering manufacturing or product characteristics.
A current Orange Book entry should be reviewed for:
- Listed patent number;
- Patent-use code;
- Submission date;
- Patent expiration date;
- Whether the patent is product-specific or method-of-use specific; and
- Whether FDA has removed, corrected, or changed the listing.
Patent 11,147,790 is potentially important to an abbreviated new drug application because its claims include both the composition and molluscum-treatment use. A Paragraph IV certification could trigger litigation if the patent is listed against the relevant reference product.
Which companies are challenging the patent?
The supplied information does not identify an ANDA filer, Paragraph IV notice, district-court complaint, settlement agreement, or inter partes review involving patent 11,147,790. No challenger or settlement should be attributed to this patent without a verified court, USPTO, FDA, or company filing.
The most relevant challenge routes are:
| Challenge route |
Potential relevance |
| Paragraph IV certification |
ANDA applicant alleges that the patent is invalid, unenforceable, or not infringed |
| Paragraph III certification |
ANDA applicant accepts the patent and delays approval until expiration |
| Inter partes review |
Third party challenges patentability based on patents or printed publications |
| Post-grant review |
Available only within the statutory period after issuance |
| District-court litigation |
Patent owner litigates infringement after a Paragraph IV notice |
| Declaratory judgment |
Potential route for a party facing a patent dispute or market uncertainty |
The composition claim may face prior-art challenges based on earlier cantharidin formulations, solvent systems, topical film-forming compositions, or combination products. The method claims may face obviousness challenges based on known cantharidin treatment of warts and molluscum contagiosum. The penetration and plasma-concentration limitations may provide additional validity arguments if the prior art does not disclose those measurements or results.
How strong is the patent estate for cantharidin products?
Patent 11,147,790 has meaningful commercial value because it combines formulation, delivery, and treatment claims in one patent. Its practical strength is mixed.
Strengths
- The composition requires a defined multi-component formulation rather than cantharidin alone.
- The open "comprising" language allows additional ingredients.
- The applicator claim can cover a prefilled single-use product.
- The molluscum and wart method claims extend beyond the composition itself.
- Residence-time and penetration claims may capture product-use instructions and clinical performance.
Weaknesses
- The central composition is narrow in ingredient identity and concentration.
- "About" creates potential claim-construction disputes.
- The penetration claims may be difficult to prove.
- The plasma limitation requires patient-specific pharmacokinetic evidence.
- A competitor may design around one required excipient or alter the concentration profile.
- Cantharidin has a long history of topical use, creating potential prior-art exposure.
The strongest enforcement position would involve a product that copies the full solvent-polymer-excipient package and is sold in a single-use applicator for molluscum treatment. A product using cantharidin in a materially different vehicle presents a more substantial design-around argument.
How does patent 11,147,790 compare with generic-entry risk?
A generic applicant would typically evaluate three paths:
- Match the reference formulation and challenge the patent through Paragraph IV.
- Delay approval until patent expiration under a Paragraph III certification.
- Develop a different formulation and pursue a regulatory pathway that does not require copying every claimed characteristic.
The third path is commercially difficult if FDA requires substantial clinical or comparative data for a materially different topical formulation. A formulation that avoids the patent may face development costs, manufacturing qualification requirements, clinical-bridging questions, and separate patent exposure.
For a small-molecule topical product, biosimilar risk is not applicable. The relevant competitors are generic drug applicants, branded cantharidin developers, compounding pharmacies, and products using alternative destructive or keratolytic agents.
What manufacturing and IP barriers matter?
The formulation includes volatile solvents, film-forming polymers, oils, camphor, and a potent vesicant. Manufacturing controls may affect:
- Cantharidin uniformity;
- Solvent evaporation;
- Viscosity;
- Film formation;
- Applicator dose consistency;
- Container compatibility;
- Stability;
- Flammability controls; and
- Worker exposure.
Those technical requirements can create commercial barriers independent of patent protection. A competitor that changes the solvent ratio or polymer system may avoid claim 1 but incur new stability and delivery problems.
The use of a single-use applicator also creates device and packaging considerations. Depending on the product configuration, separate patent families may cover the applicator, reservoir, tip, packaging, child-resistant features, or manufacturing process.
What is the likely commercial impact of a competing cantharidin product?
The commercial exposure is concentrated in molluscum contagiosum, where FDA approval provides a defined prescription market. A competing product could target the same indication, warts, or both. The patent’s claim 4 coverage for warts is commercially relevant because it extends beyond the approved molluscum indication, although FDA approval and patent enforceability are separate questions.
Market-entry risk depends on:
- Whether patent 11,147,790 is listed against the reference product;
- Whether additional formulation or device patents exist;
- Whether the challenger copies the claimed composition;
- Whether the challenger can establish a non-infringing concentration profile;
- Whether FDA accepts the proposed regulatory pathway; and
- Whether litigation produces a stay, injunction, or settlement.
A settlement agreement could limit launch through a licensed entry date, authorized-generic arrangement, or formulation restriction. No settlement terms are established by the supplied record.
Key Takeaways
- Patent 11,147,790 is centered on a defined cantharidin topical formulation containing acetone, ethanol, castor oil, nitrocellulose, hydroxypropyl cellulose, and camphor.
- Claim 1 is open-ended but formulation-specific.
- Claims 6 and 7 add denatonium benzoate and gentian violet, with claim 7 using the narrower "consists essentially of" format.
- Claims 2, 4, and 5 cover molluscum and wart treatment methods.
- Claims 8 through 12 add residence-time and plasma-exposure limitations.
- Claims 13 and 14 add 50% and 90% cantharidin penetration thresholds.
- Claim 3 covers a single-use applicator containing the claimed composition.
- The main generic strategy is formulation design-around or a Paragraph IV challenge.
- Biosimilar analysis does not apply because cantharidin is a small-molecule active ingredient.
- Patent strength is highest against products that copy the full formulation and delivery architecture.
Frequently Asked Questions
Does a 0.7% cantharidin product infringe patent 11,147,790?
Not automatically. The patent claim recites about 0.88% cantharidin, and infringement would depend on the legally construed range for "about," the full formulation, and possible equivalents.
Can a competitor avoid the patent by removing camphor?
Potentially. Camphor is a required element of claim 1. Removing it or replacing it may avoid literal infringement, although other claims, patents, or the doctrine of equivalents could remain relevant.
Does patent 11,147,790 cover over-the-counter cantharidin products?
The claims do not depend on prescription status. A product meeting the claim limitations could raise infringement issues regardless of whether it is marketed by prescription or over the counter.
Are wart treatments covered even if the approved product is indicated for molluscum contagiosum?
Yes. Claim 4 expressly recites treating warts. FDA labeling, however, determines the approved indication and does not automatically expand to every patented method.
Can a single-use applicator infringe without using the exact commercial brand?
Yes. Brand identity is not determinative. Infringement depends on whether the applicator contains a composition meeting the patent’s claim limitations and satisfies the claim’s device requirements.
References
- United States Patent and Trademark Office. (2021). U.S. Patent No. 11,147,790: Cantharidin formulations and methods of use.
- U.S. Food and Drug Administration. (2023, July 21). FDA approves first treatment for molluscum contagiosum.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC: U.S. Department of Health and Human Services.